C-Reactive Protein as a Predictor of Survival and Length of Hospital Stay in Community-Acquired Pneumonia

Introduction: Community-acquired pneumonia (CAP) presents high mortality rates and high healthcare costs worldwide. C-reactive protein (CRP) has been widely used as a biomarker for the management of CAP. We evaluated the performance of CRP threshold values and ΔCRP as predictors of CAP survival and length of hospital stay. Methods: A total of 173 adult patients with CAP were followed for up to 30 days. We measured serum CRP levels on days 1, 4, and 7 (D1, D4, and D7) of hospitalization, and their variations between different days were calculated (ΔCRP). A multivariate logistic regression model was created with CAP 30-day survival and length of hospital stay as dependent variables, and absolute CRP values and ΔCRP, age, sex, smoking habit (pack-years), pO2/FiO2 ratio on D1, WBC on D1, and CURB-65 score as independent variables. Results: A total of six patients with CAP died (30-day mortality 3.47%). No difference was found in CRP levels and ΔCRP between survivors and non-survivors. Using a cut-off level of 9 mg/dL, the AUC (95% CI) for the prediction of survival of CRP on D4 and D7 were 0.765 (0.538–0.992) and 0.784 (0.580–0.989), respectively. A correlation between CRP values on any day and length of hospital stay was found, with it being stronger for CRPD4 and CRPD7 (p < 0.0001 and p = 0.0024, respectively). A reduction of CRP > 50% from D1 to D4 was associated with 4.11 fewer days of hospitalization (p = 0.0308). Conclusions: CRP levels on D4 and D7, but not ΔCRP, could fairly predict CAP survival. A reduction of CRP > 50% by the fourth day of hospitalization could predict a shorter hospital stay.

[1]  Fernando Saldías-Peñafiel,et al.  [Immunocompetent adults hospitalized for a community-acquired pneumonia: Serum C-reactive protein as a prognostic marker]. , 2019, Revista medica de Chile.

[2]  B. Everts,et al.  C-Reactive Protein Promotes Inflammation through FcγR-Induced Glycolytic Reprogramming of Human Macrophages , 2019, The Journal of Immunology.

[3]  T. Ueland,et al.  Inflammatory biomarkers are associated with aetiology and predict outcomes in community-acquired pneumonia: results of a 5-year follow-up cohort study , 2019, ERJ Open Research.

[4]  R. Farah,et al.  Consecutive Measures of CRP Correlate with Length of Hospital Stay in Patients with Community-Acquired Pneumonia. , 2018, The Israel Medical Association journal : IMAJ.

[5]  Gernot Rohde,et al.  Failure of CRP decline within three days of hospitalization is associated with poor prognosis of Community-acquired Pneumonia , 2017, Infectious diseases.

[6]  N. Soldevila,et al.  Factors associated with 30-day mortality in elderly inpatients with community acquired pneumonia during 2 influenza seasons , 2017, Human vaccines & immunotherapeutics.

[7]  P. Ravn,et al.  The prognostic value of consecutive C-reactive protein measurements in community acquired pneumonia , 2015 .

[8]  H. Yoon Changes in the epidemiology and burden of community-acquired pneumonia in Korea , 2014, The Korean journal of internal medicine.

[9]  F. Blasi,et al.  Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. , 2013, Chest.

[10]  W. Nseir,et al.  Impact of serum C-reactive protein measurements in the first 2 days on the 30-day mortality in hospitalized patients with severe community-acquired pneumonia: a cohort study. , 2013, Journal of critical care.

[11]  L. F. Ramos-Lima,et al.  Biomarkers in community-acquired pneumonia: A state-of-the-art review , 2012, Clinics.

[12]  M. Mantero,et al.  Understanding the burden of pneumococcal disease in adults. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  T. Welte,et al.  Biomarkers in community-acquired pneumonia , 2012, Expert review of respiratory medicine.

[14]  P. Póvoa,et al.  Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study , 2012, Critical Care.

[15]  T. Schaberg,et al.  Guidelines for the management of adult lower respiratory tract infections ‐ Full version , 2011, Clinical Microbiology and Infection.

[16]  T. Welte,et al.  Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[17]  S. Mody,et al.  Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US , 2009, Current medical research and opinion.

[18]  A. Hill,et al.  C-reactive protein is an independent predictor of severity in community-acquired pneumonia. , 2008, The American journal of medicine.

[19]  P. Póvoa,et al.  Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course , 2007, Critical care.

[20]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[21]  M. Fine,et al.  Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. , 2000, The American journal of medicine.

[22]  Sheldon P Stone,et al.  Community-acquired pneumonia , 1998, The Lancet.

[23]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.

[24]  A. Ortqvist,et al.  Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. , 1995, Scandinavian journal of infectious diseases.

[25]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.